Research suggests fund managers' biggest bets outperform. That’s even true for managers of poorly performing funds, although at the Investors Chronicle, we’re only interested in the best of the best.
Every week, we publish a list of the “best ideas” of top fund managers from one of seven sectors. This week it is the turn of pharma, biotech and healthcare stocks.
Our fund managers’ best ideas tables constitute the top five holdings of a selection of top performing funds. The data is based on the funds’ most recent portfolio disclosures to Morningstar.
Is the chief executive of healthcare fund favourite AstraZeneca justifying his handsome salary?
|FUND BEST IDEAS: HEALTH|
|UnitedHealth Group Inc||5 (NEW)|
|Vertex Pharmaceuticals Inc||4|
|Johnson & Johnson||3 (NEW)|
|AbbVie Inc||2 (+1)|
|Boston Scientific Corp||2|
|Gilead Sciences Inc||2 (-1)|
|Horizon Therapeutics PLC||2 (+1)|
|Regeneron Pharmaceuticals Inc||2|
|Thermo Fisher Scientific Inc||2 (-1)|
|Alnylam Pharmaceuticals Inc||1 (+1)|
|Bio-Rad Laboratories Inc||1|
|Bristol-Myers Squibb Company||1 (NEW)|
|Eli Lilly and Co||1|
|Intuitive Surgical Inc||1 (NEW)|
|IQVIA Holdings Inc||1 (NEW)|
|Keros Therapeutics Inc||1 (NEW)|
|Merck & Co Inc||1|
|Neurocrine Biosciences Inc||1 (NEW)|
|Roche Holding AG||1|
|Sanofi SA||1 (NEW)|
|Seagen Inc Ordinary Shares||1|
|Turning Point Therapeutics Inc||1|
Learn from the best
Understanding the investment process of some of the world's top fund managers can help private investors when they're picking stocks and when they're choosing which funds to invest in. In the links below you can listen to our discussions with some of the UK's best and head to our podcast page to listen to all our fund manager interviews.
Nick Train hates selling companies so much that he can’t quite remember which stock he sold last. “Selling is an admission you’ve made a mistake,” he says in this interview with Leonora Walters.
Walter Price, portfolio manager of hugely successful Allianz Technology Trust, is concerned about the valuations of US tech companies. In this podcast, he tells us his views on growth, regulation, and China.
Tension between the US and China isn’t something that worries Roddy Snell, co-manager at Baillie Gifford’s China Fund, Emerging Markets Leading Companies Fund and Pacific Fund.